Your browser doesn't support javascript.
loading
Fluorescence Sensing of Eclampsia Biomarkers via the Immunosorbent Atom Transfer Radical Polymerization Assay.
Ma, Nan; Zhang, Jian; Kong, Jinming; Zhang, Xueji.
Afiliación
  • Ma N; School of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing, Jiangsu 210094, P. R. China.
  • Zhang J; Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing 211200, PR China.
  • Kong J; Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, PR China.
  • Zhang X; School of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing, Jiangsu 210094, P. R. China.
Anal Chem ; 96(21): 8450-8457, 2024 05 28.
Article en En | MEDLINE | ID: mdl-38728011
ABSTRACT
Accurate and quantitative detection of pre-eclampsia markers is crucial in reducing pregnancy mortality rates. This study introduces a novel approach utilizing a fluorescent biosensor by the immunosorbent atom transfer radical polymerization (immuno-ATRP) assay to detect the pre-eclampsia protein marker CD81. The critical step used in this sensor is the novel signal amplification strategy of fluorescein polymerization mediated by ferritin-enhanced controlled radical polymerization, which combines with a traditional enzyme-linked immunosorbent assay (ELISA) to further reduce the detection limit of the CD81 protein concentration. The fluorescence intensity was linear versus logarithmic CD81 protein concentration from 0.1 to 10,000 pg mL-1, and the detection limit was 0.067 pg mL-1. Surprisingly, in 30% normal human serum (NHS), the sensor can also detect target protein over 0.1-10,000 pg mL-1, with 0.083 pg mL-1 for the detection limit. Moreover, the proposed biosensor is designed to be cost-effective, making it accessible, particularly in resource-limited settings where expensive detection techniques may not be available. The affordability of this method enables widespread screening and monitoring of preeclampsia, ultimately benefiting many pregnant women by improving their healthcare outcomes. In short, developing of a low-cost and susceptible direct detection method for preeclampsia protein markers, such as CD81, through the use of the immuno-ATRP assay, has significant implications for reducing pregnancy mortality. This method holds promise for early detection, precise treatment, and improved management of preeclampsia, thereby contributing to better maternal and fetal health.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Biomarcadores / Técnicas Biosensibles / Polimerizacion Límite: Female / Humans / Pregnancy Idioma: En Revista: Anal Chem Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Biomarcadores / Técnicas Biosensibles / Polimerizacion Límite: Female / Humans / Pregnancy Idioma: En Revista: Anal Chem Año: 2024 Tipo del documento: Article